Clinical Trials Directory

Trials / Completed

CompletedNCT00325065

Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders

Status
Completed
Phase
Study type
Observational
Enrollment
71 (actual)
Sponsor
National Institute of Mental Health (NIMH) · NIH
Sex
All
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species....

Detailed description

Objective: The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Study Population: A total of 216 healthy male and female adults between 20-40 years of age. Design: This protocol will involve a series of independent studies. Each study will require one visit in addition to a screening visit, involves a physical and psychiatric assessment. The study visit itself will involve pharmacological challenge followed by neurocognitive or neuroimaging testing. Outcome Measures: Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species.

Conditions

Timeline

Start date
2006-05-05
Completion
2010-04-16
First posted
2006-05-12
Last updated
2017-07-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00325065. Inclusion in this directory is not an endorsement.